(Reuters) – The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen’s Alzheimer’s drug Leqembi, the agency said on Friday.
The safety information to be reviewed was made available after November, when the regulator had recommended approval of the drug for some patients with early Alzheimer’s disease.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Shinjini Ganguli)
Comments